UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 28, 2008
Commission File Number 000-52263
CAVIT SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Florida 03-0586935
(State or Other Jurisdiction (I.R.S Employer
of Incorporation or Organization) Identification Number)
1600 South Dixie Highway, Suite 500,
Boca Raton , Florida 33432
(Address of principal executive offices)
(561)544-6988
(Registrant's telephone number, including area code)
20 NW 181st Street, Miami, Florida 33169
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On May 28, 2008, the Registrant entered into an Asset Purchase Agreement
("Agreement") with Alternecare Health Products, Inc. ("Alternecare") pursuant to
which the Registrant agreed to acquire certain inventory, promotional materials,
displays and exhibits, customer lists, existing relationships with manufacturers
and customers, trademark and website in exchange for 250,000 restricted shares
of the Registrant's common stock and a one-year promissory note payable to
Alternecare in the principal amount of $50,000.
On May 28, 2008, the Registrant entered into a six month consulting
agreement with Ismael Gonzalez, Alternecare's President, who will consult with
and advise the Registrant with respect to the Registrant's supplement lines. Mr.
Gonzalez will receive an aggregate of $12,000 as payment for his consulting
services.
ITEM 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS
The acquisition transaction described in Item 1.01, above, was consummated
on May 28, 2008.
ITEM 7.01 REGULATION FD DISCLOSURE.
On May 30, 2008, the Registrant issued a press release related to the above
transactions. A copy of the press release is furnished as Exhibit 99.1 to this
Form 8-K and is incorporated herein by reference.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
Exhibit No. Description of Exhibit
- ----------- ----------------------
10.1 Asset Purchase Agreement between Cavit Sciences, Inc. and
Alternecare Health Products, Inc., May 28, 2008.
10.2 Agreement to Engage Ismael Gonzalez as Consultant between
Cavit Sciences, Inc. and Ismael Gonzalez, dated May 28, 2008
(included as Exhibit D to Exhibit 10.1, above).
99.1 Press release, dated May 30, 2008, regarding Asset Purchase
Agreement between Cavit Sciences, Inc. and Alternecare
Health Products, Inc. of May 28, 2008.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto authorized.
Date: May 30, 2008 Cavit Sciences, Inc.
By: /s/ Colm J. King
-------------------------------------
Colm J. King
President and Chief Executive Officer
3